

# MARKET REPORT



Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)1300 321501 or **Email:** [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com)

# Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family

## Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family

The Competitive Intelligence Report **Inhibitors of the bromodomain and extra-terminal domain (BET) family** as of January 201 provides a competitor analysis in the development pipeline of novel small molecule pan, selective or dual target bromodomain and extra-terminal domain (BET) family inhibitors suitable for treatment of cancer, inflammatory and cardiovascular diseases. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Bromodomains are epigenetic readers of histone acetylation involved in chromatin remodeling and transcriptional regulation. Bromodomains have attracted great interest as promising new epigenetic targets for diverse human diseases, including inflammation, cancer, and cardiovascular disease. The demonstration that two small molecule compounds, JQ1 and I-BET762, potently inhibit proteins of the bromodomain and extra-terminal (BET) family with potential for cancer and inflammatory disease sparked intense efforts in academia and pharmaceutical industry to develop novel bromodomain antagonists for therapeutic applications. Several BET inhibitors are already in clinical trials for hematological malignancies, solid tumors and cardiovascular disease.

The report includes a compilation of currently active projects in research and development of novel small molecules targeting for treatment of hematologic malignancies, solid tumors, inflammatory and cardiovascular diseases. In addition, the report lists company-specific R&D pipelines of BET Inhibitors. Competitor projects are listed in a tabular format providing Information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product category/Therapeutic Area,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

### About **Competitor Analysis Series**:

The Competitor Analysis Series delivers **NO-FRILLS**, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies **at low prices**. The information is provided in a tabular format and fully referenced.

## Additional Details

**Publisher :** La Merie

**Reference :** LMCA0153

**Number of Pages :** 28

**Report Format :** PDF

**Publisher Information :**



**La Merie**  
Publishing

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish reports, offer R&D database access, and provide consulting in pharmacology and biotechnology. Our products and subscription services are commercialized via our associated biotech portal PipelineReview.com.

# Table Of Contents for Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family

## **Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family**

### **Table of Contents**

- Inhibitors of the bromodomain and extra-terminal domain (BET) family
- Corporate BET Inhibitor R&D Pipelines

# How to Buy...

Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/668>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$225** | Single User Price
- \$250** | Site License Price
- \$775** | Global License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.